The data are encouraging but early (Phase 2, n=40). Monitor for Phase 3 readouts from the ROSETTA Lung-02 trial and the two other NSCLC Phase 3 trials (ROSETTA Lung-201 and -202). The broad registrational program (7 Phase 3 trials) suggests high optionality, but de-risking requires larger datasets. No financial impact until regulatory approval.
Price Chart
Executive Summary
BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) plus chemotherapy in first-line non-small cell lung cancer. The data showed a confirmed objective response rate of 57.1% in non-squamous and 68.4% in squamous NSCLC, with a 100% disease control rate, and a manageable safety profile. This is a positive clinical update for a key pipeline asset, but the data are early-stage (Phase 2, n=40) and the stock impact is likely modest given the pre-revenue nature of the company.
Key Facts
- Interim Phase 2 data from ROSETTA Lung-02 trial of pumitamig (BNT327/BMS-986545) plus chemotherapy in first-line advanced NSCLC.
- Confirmed objective response rate (cORR) of 57.1% in non-squamous and 68.4% in squamous NSCLC; disease control rate (DCR) of 100%.
- At the lower dose, cORR was 63.6% for non-squamous and 72.7% for squamous subtypes.
- cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%).
- Grade 3 treatment-related adverse events in 48.8% of patients; treatment discontinuation in 9.3%.
- Phase 3 part of ROSETTA Lung-02 is actively enrolling; two additional global Phase 3 trials in NSCLC are also enrolling.
- Seven global Phase 3 trials with registrational potential are ongoing across multiple indications.
Financial Impact
No financial figures provided in the filing. Pumitamig is an investigational asset with no approved products or disclosed revenue.
Risk Factors
- Phase 2 data are from a small sample (n=40) and may not replicate in larger Phase 3 trials.
- Safety profile includes Grade 3 TRAEs in 48.8% of patients and a 9.3% discontinuation rate, which could limit commercial potential.
- Pumitamig is pre-revenue; BioNTech's stock remains tied to pipeline milestones and COVID vaccine revenue trends, not disclosed here.
- Competition from existing PD-(L)1 and VEGF inhibitors (e.g., Keytruda, Avastin) and other bispecifics in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000039 |
| Document: form6-kascopumitamignsclc1.htm | 0001776985-26-000039 |
| Document: 0001776985-26-000039-index-headers.html | 0001776985-26-000039 |
| Document: 0001776985-26-000039-index.html | 0001776985-26-000039 |
| Document: 0001776985-26-000039.txt | 0001776985-26-000039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access